WuXi AppTec Co

WuXi AppTec Co Debt

The Debt of WuXi AppTec Co (603259.SS) as of Nov 21, 2026 is 8.42 B CNY. In the previous year, Debt was 4.75 B CNY — a change of 77.31% (higher).

Debt

8.42 BCNY

YoY

77.31%

Last updated:

In 2025, WuXi AppTec Co's total debt was 8.42 B CNY, a 77.31% change from the 4.75 B CNY total debt recorded in the previous year.

The WuXi AppTec Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
1.85 B CNY
Jan 1, 2019
7.52 B CNY
Jan 1, 2020
5.93 B CNY
Jan 1, 2021
5.62 B CNY
Jan 1, 2022
6.99 B CNY
Jan 1, 2023
5.45 B CNY
Jan 1, 2024
4.75 B CNY
Jan 1, 2025
8.42 B CNY
The WuXi AppTec Co Debt history
YEARDebtYoY
8.42 BCNY+77.31%
4.75 BCNY-12.91%
5.45 BCNY-22.03%
6.99 BCNY+24.50%
5.62 BCNY-5.27%
5.93 BCNY-21.14%
7.52 BCNY+305.70%
1.85 BCNY+13.35%
1.64 BCNY+231.79%
492.84 MCNY+181.22%
175.25 MCNY-84.63%
1.14 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WuXi AppTec Co Stock analysis

What does WuXi AppTec Co do? WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore. The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services. In terms of various industries, the company is divided into three main divisions. The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time. The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services. The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies. In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation. The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools. The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry. WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding WuXi AppTec Co's Debt Structure

WuXi AppTec Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing WuXi AppTec Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to WuXi AppTec Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in WuXi AppTec Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about WuXi AppTec Co stock

Debt of WuXi AppTec Co is 8.42 B CNY in 2025.

Debt of WuXi AppTec Co changed from 4.75 B CNY to 8.42 B CNY, representing a 77.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt WuXi AppTec Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's WuXi AppTec Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — WuXi AppTec Co

All Key Metrics — WuXi AppTec Co